Chronic myelomonocytic leukaemia
British Journal of Haematology · 2025
DOI: 10.1111/bjh.70226 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Ayalew Tefferi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Leukemia, Myelomonocytic, Chronic. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
Chronic myelomonocytic leukaemia (CMML) is a morphological hybrid between myelodysplastic and myeloproliferative neoplasms and is characterized by clonal monocytosis. Myeloid neoplasm‐associated somatic mutations are present in >90% of patients with CMML but are not diagnostically specific but a subset are prognostically relevant. Current drug therapy in CMML is mostly palliative and not disease‐modifying. Allogeneic haematopoietic stem cell transplantation is a potentially curative treatment modality in CMML and its timing is determined by formal prognostic models including the recently developed BLAST and BLAST‐molecular risk models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Ayalew Tefferi
Zitieren
APA
Tefferi, A., & Patnaik, M. M. (2025). Chronic myelomonocytic leukaemia. British Journal of Haematology. https://doi.org/10.1111/bjh.70226
Vancouver
Tefferi A, Patnaik MM. Chronic myelomonocytic leukaemia. British Journal of Haematology. 2025. doi:10.1111/bjh.70226
BibTeX
@article{Tefferi2025,
author = {Tefferi, Ayalew and Patnaik, Mrinal M},
title = {Chronic myelomonocytic leukaemia},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.70226}
}
EUVIMED